- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02580045
Pharmacokinetics of Systemic Anti-Cancer Therapies in the Cerebrospinal Fluid (CSF) of Patients With Advanced Cancer
CSF Pharmacokinetics of Systemic Anti-Cancer Therapies in Patients With Advanced Cancer
Study Overview
Status
Detailed Description
Very little is known about the penetration of systemic therapies through the normal blood brain barrier and the ways in which a brain metastasis or radiation would impact the permeability of the blood brain barrier. This study would be one of the first to examine the concentrations of systemic cancer therapies in the cerebrospinal fluid (CSF) with matched serum samples. Additionally, the concentration of these therapies in brain metastasis surgical specimens would be of particular interest to correlate with serum and CSF levels, length of time on therapy, and latency to developing brain metastases in future studies.
As participants in this study, patients scheduled for a lumbar puncture per their standard of care treatment will be subject to a withdrawal of 15cc's of cerebrospinal fluid for pharmacokinetic analysis. They will also have a blood draw of 5mL within 2 hours of the lumbar puncture for serum pharmacokinetics. If the patient is eligible for and elects to proceed with surgical resection of a brain metastasis, optional CSF and serum samples would be drawn at the time of resection.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Metastatic cancer patients on systemic anti-cancer therapy (chemotherapy, endocrine therapy, HER2 targeted therapy, immune therapy).
- Patients must be able to have a lumbar puncture within 2 half-lives of the last dose of systemic therapy.
- Patients undergoing an LP for any reason with known advanced cancer on systemic anti-cancer therapy are eligible.
- Patients with new or previously treated brain metastases are eligible.
- Patients may have received prior stereotactic radiosurgery to the brain and/or whole brain radiation.
- No limitations on prior systemic or intrathecal therapies.
- There are no restrictions on systemic therapy at enrollment.
- Laboratory criteria: normal renal function: creatinine < 1.5 x upper limit of normal (ULN)), liver function: bilirubin < 1.5 x ULN, transaminases < 2 x ULN, except in known hepatic disease, wherein may be < 5 x ULN, and blood counts: WBC ≥ 2.0, Neutrophils ≥1500, platelets ≥100,000, Hemoglobin ≥ 10.
- Age > 18 years
- Patients must have the ability to give informed consent.
- Patients must have a signed informed consent form prior to enrollment on study.
Exclusion Criteria:
- No history of lumbar surgery or other pre-existing spinal conditions that would preclude a safe, reliable lumbar puncture.
- Patients should have no significant psychiatric illness or medical illness that would preclude the ability to comply with the protocol.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The concentration of drug metabolites of systemic anti-cancer therapies in the cerebrospinal fluid
Time Frame: up to 3 weeks
|
CSF pharmacokinetics of systemic anti-cancer therapies, as measured by the concentration of their metabolites in the cerebrospinal fluid, will be obtained via lumbar puncture.
The lumbar puncture will take place within 2 half-lives of the last dose of systemic therapy.
Because a wide variety of anti-cancer therapies will be studied in this trial, there is significant variability in the half-lives of these therapies.
Some will take place 2-24 hours after the last dose of systemic therapy.
Some will take place 1-6 days after the last dose of systemic therapy.
Some will take place 1-3 weeks after the last dose of systemic therapy.
The time of the lumbar puncture procedure will depend greatly on the identity of the systemic therapy with which the subject is being treated.
In patients undergoing surgical resection of a brain metastasis, an additional CSF sample is optional.
|
up to 3 weeks
|
Ratio of serum to CSF concentration of systemic anti-cancer therapies as measured by concentration of drug metabolites in serum and in CSF
Time Frame: up to 3 weeks
|
CSF and serum pharmacokinetics of systemic anti-cancer therapies, as measured by the concentration of their metabolites, will be obtained via lumbar puncture and blood draw, respectively.
The lumbar puncture and blood draw will take place together within 2 half-lives of the last dose of systemic therapy.
Because a wide variety of anti-cancer therapies will be studied in this trial, there is significant variability in the half-lives of these therapies.
Some will take place 2-24 hours after the last dose of systemic therapy.
Some will take place 1-6 days after the last dose.
Some will take place 1-3 weeks after the last dose.
The time of the lumbar puncture procedure will depend greatly on the identity of the systemic therapy with which the subject is being treated.
In patients undergoing surgical resection of a brain metastasis, an additional matched CSF and serum sample is optional.
|
up to 3 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kimberly L Blackwell, MD, Duke University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00062142
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Cancer
-
STORM Therapeutics LTDRecruitingCancer | Advanced Solid Tumor | Advanced CancerUnited States
-
Merck Sharp & Dohme LLCCompletedAdvanced Cancer Relapsed | Advanced Cancer Refractory
-
BiOneCure Therapeutics Inc.RecruitingCancer | Advanced Solid Tumor | Advanced Cancer | OncologyUnited States
-
Teon Therapeutics, Inc.Merck Sharp & Dohme LLCTerminatedCancer | Advanced Solid Tumor | Advanced Cancer | OncologyUnited States
-
Zhejiang UniversityRecruitingAdvanced Colorectal Cancer | Advanced Hepatocellular Carcinoma | Advanced Gastric Cancer | Advanced Pancreatic CancerChina
-
PfizerTerminatedAdvanced Solid Tumors | Advanced CancerUnited States
-
AVEO Pharmaceuticals, Inc.CompletedAdvanced Cancer | Refractory CancerUnited States
-
Avera McKennan Hospital & University Health CenterCompleted
-
AstraZenecaTerminatedCancer | Advanced Solid Tumors | Advanced Solid MalignanciesUnited States
-
Bristol-Myers SquibbRecruitingAdvanced CancerUnited States, Spain, Belgium, Argentina, Korea, Republic of, Japan